The global endometrial ablation market size was estimated at USD 1.13 billion in 2022 and is expected to grow at a compound annual growth (CAGR) of 5.16% from 2023 to 2030. This can be attributed to the increasing demand for endometrial ablation devices owing to the rising prevalence of gynecological disorders, such as PCOD, and menorrhagia, and rising public awareness about the procedure. According to the Centers for Disease Control and Prevention (CDC), 10 million women in the U.S. suffer from menorrhagia each year. The competitive advantage of endometrial ablation over other surgical procedures, such as minimal invasiveness, is expected to boost the demand for devices in the coming years.
The growing percentage of patients affected by menorrhagia, which is also referred to as heavy or abnormal menstrual bleeding, is anticipated to boost market growth during the forecast period. As per the FDA, heavy menstrual bleeding is a common problem for many women. Around 1/3 of women who get their period seek medical attention for heavy bleeding. Bleeding that exceeds 1/3 cup (80 ml) is considered heavy/excessive. Women’s health is a priority for governments and private organizations worldwide.
Women's coverage plans are one of the primary elements projected to drive industry growth in developed countries. For instance, in India, numerous tax benefits and exemptions are available to women under various sections of the income tax legislation; one is the income tax deduction, which can be claimed on premiums paid for health insurance policies. Such initiatives concerning women’s health may increase the adoption of treatment options available for them, including endometrial ablation, thus boosting the market growth.
Several players are undertaking various strategies to strengthen their market positions. For instance, in February 2022, the Cooper Companies, Inc. signed a legal agreement to acquire Cook's Medical's reproductive health business. Cook Medical manufactures minimally invasive medical devices focused on obstetrics, gynecology, and fertility. This acquisition enables companies to expand their product portfolios, increase their capabilities, and improve their competencies.
The radiofrequency ablation segment accounted for the largest market share of 55.89% in 2022. The growth is driven by the product’s convenience, speed of treatment, efficacy, and cost-efficiency compared to other ablation devices. In addition, radiofrequency ablation devices are widely available and are well-known among physicians. In December 2022, the U.S. FDA approved the Mygen M-3004 generator and specialized electrodes, including Myoblade, developed by RF Medical. This product is indicated for the treatment of uterine fibroids while keeping the uterus intact.
The others segment is anticipated to grow significantly during the forecast period. This segment primarily includes electrical ablators, hysteroscopes, and resectoscopes. The increasing number of procedures, such as hysterectomies, is projected to fuel future demand for hysteroscopic endometrial ablation. According to the University of Michigan, over 40,000 hysterectomies are performed in the U.S. annually. Therefore, huge opportunities are available for other endometrial ablation products globally.
The clinics end-use segment accounted for the largest revenue share of 53.65% in 2022. This can be attributed to the implementation of innovative technologies for treating menorrhagia, increasing awareness about the use of endometrial ablation devices, expanding clinical trials on endometrial ablation methods, and increased government research allocations for the widespread availability of healthcare devices. The hospitals segment is expected to witness significant growth during the forecast period.
This can be attributed to a rise in the number of patients being hospitalized for gynecological disorders, as hospitals provide excellent care as well as reimbursements. Also, hospitals possess advanced treatment devices, which contributes to the expansion of this segment. In addition, due to the ease of managing any problems that may develop during surgical procedures and the availability of a wide range of treatment options in the facility, hospitals see a substantially higher inflow of patients for gynecological treatments than other healthcare settings.
North America accounted for the largest share of 32.05% in 2022. This can be attributed to rising cases of gynecological disorders, the presence of key market players, and rising preference for minimally invasive surgical procedures. In the U.S., patient outcomes and safety are of the utmost importance, and various projects have been established to improve healthcare quality and lower costs. Higher healthcare spending in North America than in other regions contributes to the region's growth.
The Asia Pacific region is expected to witness the fastest growth rate during the forecast period. The COVID-19 pandemic has highlighted the region’s health system’s inadequacies & flaws and the interdependence of health security and economic stability. As a result, the region is progressing toward obtaining Universal Health Care, or UHC. Furthermore, the market is expected to develop due to an increase in the prevalence of menorrhagia and a rise in demand for innovative technology.
New product launches, collaborations, and partnerships are among the key strategies adopted by major players to gain a competitive edge that positively contributes to market growth. For instance, in February 2023, Hologic Inc. received approval for its NovaSure V5 Global Endometrial Ablation (GEA) in Europe and Canada. This product was indicated for AUB. Some of the prominent players in the global endometrial ablation market include:
Medtronic
The Cooper Companies, Inc.
Boston Scientific Corporation
Johnson & Johnson Service Inc.
Olympus Corporation
Richard Wolf GmbH
AngioDynamics
Hologic, Inc.
Minerva Surgical, Inc.
Report Attribute |
Details |
Market size value in 2023 |
USD 1.19 billion |
Revenue forecast in 2030 |
USD 1.69 billion |
Growth rate |
CAGR of 5.16% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; India; Japan; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa, Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Medtronic; The Cooper Companies, Inc.; Boston Scientific Corp.; Johnson & Johnson Service Inc.; Olympus Corp.; Richard Wolf GmbH; AngioDynamics; Hologic, Inc.; Minerva Surgical, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the endometrial ablation market report on the basis of product, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Cryoablation
Radiofrequency Ablation
Hydrothermal Ablation
Thermal Balloon
Microwave Energy
Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Clinics
Ambulatory Surgical Centers
Region Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global endometrial ablation market size was valued at USD 1.13 billion in 2022 and is anticipated to reach USD 1.19 billion in 2023.
b. The global endometrial ablation market is expected to witness a compound annual growth rate of 5.16% from 2023 to 2030 to reach USD 1.69 billion by 2030.
b. Based on product, the radiofrequency ablation segment accounted for a share of 55.89% in 2022 due to growing use of radiofrequency ablation in different healthcare settings for treating various tumors and abnormal uterine bleeding (AUB).
b. Some of the key players in endometrial ablation market are Medtronic; the Cooper Companies, Inc.; Boston Scientific Corporation; Johnson & Johnson Service Inc.; Olympus Corporation; Richard Wolf GmbH; AngioDynamics; Hologic, Inc.; Minerva Surgical, Inc.; among others.
b. The major factors driving the market growth are rising number of uterine problems and increasing preference toward minimally invasive surgical procedures.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."